• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cibus Appoints Co-Founder Rory Riggs, as Chief Executive Officer

    10/7/21 9:00:00 AM ET
    $FGEN
    $ITCI
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FGEN alert in real time by email

    Cibus, a leading agricultural biotechnology company, announced today the appointment of Rory Riggs, co-founder, and Chairman of Cibus, to serve as Chief Executive Officer. He will succeed Peter Beetham, PhD, also a Cibus co-founder, who has been appointed President and Chief Operating Officer of the 20-year-old company.

    "Since our founding, Rory has been an important strategic partner in the success of Cibus and we are pleased that he is deepening his involvement in the company's growth as CEO," said Dr. Beetham. "With the recent progress toward a European approval of Cibus' proprietary precision gene-editing technology, as well as other recent Cibus commercial announcements, this management shift is an important step in scaling Cibus to address the enormous opportunities that exist in the global agriculture solutions market."

    "Cibus' Rapid Trait Development System™ technology is set to play a leading role in the global drive to make farming more efficient and sustainable. The tremendous technological breakthroughs in gene editing by our scientists and others, have placed agriculture at a major point of inflection in the use of environmentally sound biological solutions to address both farming sustainability and agriculture's impact on climate change," said Mr. Riggs.

    "Cibus' focus is productivity improvements in the major row crops: canola, rice, soybean, wheat, and corn. These crops are grown annually on billions of acres of land. Addressing the use of chemicals and the impact of climate change on these major global crops is critical to achieving virtually every sustainable development and climate goal. I am excited to work more closely with the team at Cibus in this enormous opportunity to make Cibus a global leader in the transformation of agriculture."

    Mr. Riggs has an extensive record of executive leadership and innovation in the healthcare and biotechnology fields. He is a co-founder, former Chairman and director of Royalty Pharma (NASDAQ:RPRX), the largest acquirer of pharmaceutical royalties and leading funder of innovation in the life sciences. In addition, he has co-founded and served on the board of several important biotechnology companies including Sugen (NASDAQ:SUGN) and Fibrogen (NASDAQ:FGEN).

    Previously, Mr. Riggs served as President and director of Biomatrix, Inc. (NYSE:BXM) from 1996 until its sale to Sanofi/Genzyme. During his tenure, he led the development and global commercial launch of an important new category for the treatment of osteoarthritis: viscosupplementation; and the leading product in the category: Synvisc®. Mr. Riggs also served as CEO of RF&P Corp., an investment company owned by the Virginia Retirement System until its sale to Lazard. He is a Director of Intra-cellular Therapies, Inc (NASDAQ:ITCI); Stage Zero Life Sciences (OTC:SZLSF), and a co-founder and Partner of Scientia Ventures LLC, a leading venture investor in Cibus. He was formerly a Managing Director at PaineWebber, Inc.

    Mr. Riggs is also a pioneer in the field of Systems Economics and the inventor of a new information system called FIS® (Functional Information System) for the functional mapping of systems data in biology and economics. This technology is covered by several patents of which one is with Dr. Beetham and Greg Gocal, PhD, Cibus' Chief Scientific Officer. FIS is currently the basis for two investment and research analytics companies: Syntax LLC and Locus Analytics LLC.

    "The addition of Rory to our executive team is a major step in accomplishing our goal of redefining and reshaping the agricultural crop protection business," said Dr. Gocal, co-founder, Chief Scientific Officer and Executive Vice President at Cibus. "The continued technological breakthroughs in genomics and gene editing have created a generational moment in one of the most exciting scientific periods of our lifetime and we look forward to making significant contributions to improve farming through biology."

    Mr. Riggs received his BA from Middlebury College and his MBA from Columbia University's Graduate School of Business.

    About Cibus

    Cibus is a leading agricultural biotechnology company that uses precision gene editing to breed plants with new genetic traits that make them healthier and better able to thrive in their changing environments. Cibus' traits improve farming productivity by increasing crop yields and reducing inputs such as fungicides, herbicides, pesticides, and fertilizers. Cibus' trait products are important drivers of farming sustainability and the reduction of agriculture's carbon footprint. For more information, please visit www.cibus.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005383/en/

    Get the next $FGEN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FGEN
    $ITCI
    $RPRX

    CompanyDatePrice TargetRatingAnalyst
    Royalty Pharma plc
    $RPRX
    1/30/2026$49.00Neutral → Buy
    UBS
    Royalty Pharma plc
    $RPRX
    9/30/2025$42.00Buy
    Goldman
    Royalty Pharma plc
    $RPRX
    5/16/2025$51.00Overweight
    Morgan Stanley
    Intra-Cellular Therapies Inc.
    $ITCI
    2/24/2025$140.00 → $132.00Outperform → Neutral
    Mizuho
    Intra-Cellular Therapies Inc.
    $ITCI
    1/31/2025$119.00 → $132.00Buy → Hold
    Canaccord Genuity
    Intra-Cellular Therapies Inc.
    $ITCI
    9/6/2024$68.00 → $92.00Neutral → Overweight
    Piper Sandler
    Royalty Pharma plc
    $RPRX
    6/3/2024$28.00Buy → Neutral
    UBS
    Intra-Cellular Therapies Inc.
    $ITCI
    1/3/2024$83.00Outperform
    Robert W. Baird
    More analyst ratings

    $FGEN
    $ITCI
    $RPRX
    SEC Filings

    View All

    SEC Form 8-K filed by Royalty Pharma plc

    8-K - Royalty Pharma plc (0001802768) (Filer)

    6/4/26 4:15:59 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - Royalty Pharma plc (0001802768) (Filer)

    5/28/26 4:01:40 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Royalty Pharma plc

    144 - Royalty Pharma plc (0001802768) (Subject)

    5/14/26 5:28:06 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    $ITCI
    $RPRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Wettig Thane bought $33,750 worth of shares (3,700 units at $9.12), increasing direct ownership by 17% to 24,939 units (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    11/17/25 4:42:52 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Schoeneck James A bought $119,485 worth of shares (23,567 units at $5.07) (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    7/2/25 4:33:27 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Wettig Thane bought $50,663 worth of shares (145,000 units at $0.35), increasing direct ownership by 36% to 543,329 units (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    3/25/25 9:00:05 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    $ITCI
    $RPRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference

    NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 4:00 p.m. ET. The webcast will be accessible from Royalty Pharma's "Events" page at https://www.royaltypharma.com/investors/events/. Webcasts will also be archived for a minimum of thirty days. About Royalty Pharma plc Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profi

    6/4/26 4:15:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma to present at upcoming investor conferences

    NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: BofA Securities 2026 Healthcare Conference on Wednesday, May 13 at 1:40 p.m. ET / 10:40 a.m. PTRBC Capital Markets 2026 Global Healthcare Conference on Tuesday, May 19 at 10:00 a.m. ET The webcasts will be accessible from Royalty Pharma's "Events" page at https://www.royaltypharma.com/investors/events/. Webcasts will also be archived for a minimum of thirty days. About Royalty Pharma plc Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innov

    5/7/26 4:15:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma reports first quarter 2026 results

    Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13%Net cash provided by operating activities of $718 millionRaised full year 2026 guidance: Portfolio Receipts expected to be $3,325 million to $3,450 million NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the first quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts. "Royalty Pharma has delivered a strong start to 2026 across multiple dimensions. We grew Royalty Receipts by 13% and announced up to $1.25 billion of royalty transactions in the first quarter," said Pablo Legorreta, Royalty Pharma's Chief Executive Officer a

    5/6/26 7:00:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    $ITCI
    $RPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & CFO Coyne Terrance P. sold $3,476,116 worth of Class A Ordinary Shares (64,399 units at $53.98) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Royalty Pharma plc (0001802768) (Issuer)

    5/28/26 4:48:21 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Research & Investments Urist Marshall sold $721,838 worth of Class A Ordinary Shares (13,684 units at $52.75) as part of a pre-agreed trading plan, decreasing direct ownership by 43% to 18,197 units (SEC Form 4)

    4 - Royalty Pharma plc (0001802768) (Issuer)

    5/21/26 9:20:12 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Norden Gregory sold $161,385 worth of Class A Ordinary Shares (3,045 units at $53.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 191,803 units (SEC Form 4)

    4 - Royalty Pharma plc (0001802768) (Issuer)

    5/15/26 4:37:04 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    $ITCI
    $RPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Royalty Pharma upgraded by UBS with a new price target

    UBS upgraded Royalty Pharma from Neutral to Buy and set a new price target of $49.00

    1/30/26 6:41:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Royalty Pharma with a new price target

    Goldman initiated coverage of Royalty Pharma with a rating of Buy and set a new price target of $42.00

    9/30/25 8:57:42 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Royalty Pharma with a new price target

    Morgan Stanley initiated coverage of Royalty Pharma with a rating of Overweight and set a new price target of $51.00

    5/16/25 8:05:49 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    $ITCI
    $RPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by FibroGen Inc

    SC 13G/A - FIBROGEN INC (0000921299) (Subject)

    11/14/24 4:52:23 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by FibroGen Inc

    SC 13G/A - FIBROGEN INC (0000921299) (Subject)

    11/12/24 4:01:23 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by FibroGen Inc

    SC 13G/A - FIBROGEN INC (0000921299) (Subject)

    11/12/24 2:33:26 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    $ITCI
    $RPRX
    Financials

    Live finance-specific insights

    View All

    Royalty Pharma reports first quarter 2026 results

    Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13%Net cash provided by operating activities of $718 millionRaised full year 2026 guidance: Portfolio Receipts expected to be $3,325 million to $3,450 million NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the first quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts. "Royalty Pharma has delivered a strong start to 2026 across multiple dimensions. We grew Royalty Receipts by 13% and announced up to $1.25 billion of royalty transactions in the first quarter," said Pablo Legorreta, Royalty Pharma's Chief Executive Officer a

    5/6/26 7:00:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma Declares Second Quarter 2026 Dividend

    NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on June 10, 2026, to shareholders of record at the close of business on May 15, 2026. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Roya

    4/17/26 8:30:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026

    NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the "Investors" page of the company's website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days. About Royalty Pharma Founded in 1996, Royalty Pharma is th

    4/15/26 4:15:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    $ITCI
    $RPRX
    Leadership Updates

    Live Leadership Updates

    View All

    Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence

    NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and implementation of artificial intelligence capabilities across Royalty Pharma. "Lucas's appointment marks a significant step in our commitment to implementing cutting‑edge technology across our platform," said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. "By incorporating intelligent automation, advanced analytics and AI-driven decision support, we are strengthening how we evaluate and invest in royalties and support our partners. Luc

    3/23/26 7:15:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma Announces Expansion of Leadership Team

    NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced an expansion of its leadership team. Greg Butz will join Royalty Pharma as Executive Vice President, Partnering & Investments, effective June 2026. Greg joins Royalty Pharma from Bank of America, where he was the Global Co-Head of Healthcare Investment Banking. "We are thrilled that Greg will join Royalty Pharma and strengthen our leadership team," said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. "Greg brings tremendous experience advising healthcare companies on capital raising, strategy, and mergers and acquisitions and he will be a critical addition t

    3/17/26 4:01:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform

    NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty business in Asia. Ken joins Royalty Pharma from Morgan Stanley, where he was Head of Asia Pacific Healthcare Investment Banking. Asia-based biotechnology companies are now prolific creators of innovative therapeutics. In 2025, the out-licensing of Chinese medicines alone comprised over $130 billion of announced transaction value, up from approximately $14 billion in 2021, as multinational pharmaceutical companies increasingly recognized the va

    3/2/26 7:00:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care